Get Our FREE Newsletter

Sign Up

ObsEva To Work With Syneos Health On Commercialization Of Linzagolix – Quick Facts

Spread the love

(RTTNews) – ObsEva SA (OBSV) announced a strategic relationship with Syneos Health (SYHN) to commercialize linzagolix, an oral GnRH antagonist which is pending regulatory approval in the U.S. and Europe for the treatment of uterine fibroids.

This post was originally published on this site